Research & Education

Early Study Shows that Two Targeted Drugs with Chemotherapy Is Safe and Effective in Advanced NSCLC

Cetuximab and Bevacizumab Added to Chemotherapy

DENVER – A phase II study is the first to show that adding two targeted therapy drugs to the standard chemotherapy regimen is safe and effective as first-line treatment of advanced non-small-cell lung cancer (NSCLC)...

Clinicians Rate Patients with Lung Cancer with Poorer Quality of Life

Comparison with Patients with Other Types of Cancer

DENVER – Advances have been made in the treatment of lung cancer, but the disease continues to be a challenge to treat, primarily because of a high number of people who have late-stage cancer at the time of diagnosis, the likelihood of poor outcomes, and a greater symptom burden.

Soy may help protect lung cancer patients from side effects of radiation, initial study on mice

Latest in November issue of Journal of Thoracic Oncology

DENVER – Radiotherapy is a common treatment for patients with non–small-cell lung cancer. However, the side effects can include skin injury, hair loss, increased breathing rates, inflammation of the lung and fibrosis. Researchers from the Barbara Ann Karmanos Cancer Institute wanted to know if using soy isofavones would decrease toxicity.

Radiotherapy’s role in malignant airway obstruction

Latest in November issue of Journal of Thoracic Oncology

DENVER – Malignant airway obstruction is a common cause of ICU admission, often because of lung cancers, lymphoma or other thoracic malignancies. Severe cases are life threatening, and although therapeutic bronchoscopic intervention may assist in restoring airway patency and facilitating extubation, many patients are ineligible for such intervention. For patients requiring intubation and mechanical ventilation because of malignant airway obstruction, the efficacy of radiotherapy for achieving extubation is unknown. Although external beam radiotherapy is a cornerstone of treatment for lung cancer, the use of it in intubated patients is uncertain.

Researchers believe arsenic-induced lung tumors caused by different molecular mechanisms than common lung cancer

Latest in November issue of Journal of Thoracic Oncology


IASLC Names Fred R. Hirsch, MD, PhD as New CEO

Dr. Hirsch will replace Dr. Paul A. Bunn, Jr. after World Conference in 2013

The International Association for the Study of Lung Cancer (IASLC) Board of Directors has selected Fred R.